Cite

HARVARD Citation

    Beauvais, D. et al. (n.d.). P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION. HemaSphere. pp. 1209-1210. [Online]. 
  
Back to record